Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | VDR | P11473 | 4/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.33 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | ESRRB | O95718 | 1/20 | 0.32 |
| ▸ | ESRRG | P62508 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709306 | 0.99 | CXCR2 (0.35) | HDAC6HDAC3CXCR2EPHX2VDR | |
| SCHEMBL13709272 | 0.85 | PPARG (0.38) | HDAC6HDAC3EPHX2VDRPPARG | |
| SCHEMBL13709312 | 0.84 | PPARG (0.38) | HDAC6EPHX2VDRPPARGPPARD | |
| SCHEMBL13709269 | 0.83 | VDR (0.37) | HDAC6HDAC3EPHX2VDRPPARG | |
| SCHEMBL13709307 | 0.83 | VDR (0.37) | HDAC6HDAC3VDRPPARGPPARD | |
| SCHEMBL13709273 | 0.83 | CXCR2 (0.33) | HDAC6HDAC3CXCR2EPHX2VDR | |
| SCHEMBL13709309 | 0.82 | CXCR2 (0.34) | HDAC6HDAC3CXCR2EPHX2VDR | |
| SCHEMBL13712274 | 0.82 | CXCR2 (0.38) | HDAC6CXCR2VDRCYP26A1CYP26B1 | |
| SCHEMBL13709283 | 0.82 | HDAC3 (0.33) | HDAC6HDAC3VDRAR | |
| SCHEMBL13709332 | 0.81 | HDAC3 (0.33) | HDAC6HDAC3VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200552-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | HDAC6 4464/4885HDAC3 1756/4885CXCR2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.